Urology
Volume 68, Issue 2, Supplement , Pages 38-48 , August 2006

The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis

  • Vik Khullar

      Affiliations

    • Department of Obstetrics and Gynaecology, St. Mary’s Hospital, London, United Kingdom
    • Corresponding Author InformationReprint requests: Vik Khullar, MD, Department of Obstetrics and Gynaecology, Mint Wing, St. Mary’s Hospital, Norfolk Place, London W2 1PG.
    • Vik Khullar has been an investigator for Pfizer Inc, Yamanouchi, GlaxoSmithKline, AstraZeneca, and Schwartz; has served as an advisor for Pfizer Inc, Astellas, Lilly, and Schwartz; and received a grant from Pfizer Inc.
    • ,
  • Christopher Chapple

      Affiliations

    • Urology Research, Royal Hallamshire Hospital, Sheffield, United Kingdom
    • Christopher Chapple is a scientific consultant to Pfizer Inc, Astellas, Novartis, and Schwarz.
    • ,
  • Zahava Gabriel

      Affiliations

    • Heron Evidence Development Ltd., Letchworth Garden City, Herts, United Kingdom
    • Zahava Gabriel is a consultant to Pfizer Inc.
    • ,
  • Julie Ann Dooley

      Affiliations

    • Pfizer Ltd, Tadworth, Surrey, United Kingdom
    • Julie Ann Dooley is an employee of Pfizer Inc.

References 

  1. Abrams P , Cardozo L , Fall M , et al.   The standardisation of terminology in lower urinary tract function (report from the standardisation sub-committee of the International Continence Society) . Urology . 2003;61:37–49
  2. Abrams P , Kelleher C , Lerr L , et al.   Overactive bladder significantly affects quality of life . Am J Manag Care . 2000;6:S580–S590
  3. Chiaffarino F , Parazzini F , Lavezzari M , et al.   Impact of urinary incontinence and overactive bladder on quality of life . Eur Urol . 2003;43:535–538
  4. Milsom I , Irwin DE , Kopp Z , et al.   Impact of overactive bladder symptoms on employment, symptom perception and emotional well-being in 6 European countries . 2004; Presented at the 3rd International Consultation on Incontinence; June 26-29, Monte Carlo, Monaco.
  5. Herbison P , Hay-Smith J , Ellis G , et al.   Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder (systematic review) . BMJ . 2003;326:841–844
  6. Donovan J , Badia X , Corcos J , et al.   Committee 6 (symptom and quality of life assessment) . In:  Abrams P ,  Cardozo L ,  Khoury S , et al. editor. Incontinence . Plymouth, United Kingdom: Plymbridge Distributors, Ltd; 2002;p. 267–316
  7. Mattiasson A , Djurhuus JC , Fonda D , et al.   Standardization of outcome studies in patients with lower urinary tract dysfunction (a report on general principles from the Standardisation Committee of the International Continence Society) . Neurourol Urodyn . 1998;17:249–253
  8. Ushiroyama T , Ikeda A , Ueki M . Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence (improvement in quality of life) . J Med . 2000;31:311–319
  9. Burgio KL , Locher JL , Roth DL , et al.   Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women . J Gerontol B Psychol Sci Soc Sci . 2001;56:P46–P51
  10. Kelleher CJ , Reese PR , Pleil AM , et al.   Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder . Am J Manag Care . 2002;8:S608–S615
  11. Homma Y , Kawabe K . Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin (a randomized, placebo-controlled trial) . World J Urol . 2004;22:251–256
  12. Zinner N , Gittelman M , Harris R , et al.   Trospium chloride improves overactive bladder symptoms (a multicenter phase III trial) . J Urol . 2004;171:2311–2315
  13. Kelleher CJ , Cardozo L , Chapple CR , et al.   Improved quality of life in patients with overactive bladder symptoms treated with solifenacin . BJU Int . 2005;95:81–85
  14. Coyne KS , Kelleher CJ . Clinical versus patient outcomes (whose outcome has greater value?) . BMJ . 2003; [online; rapid response] Nov
  15. Chapple C , Khullar V , Gabriel Z , et al.   The effects of antimuscarinic treatments in overactive bladder (a systematic review and meta-analysis) . Eur Urol . 2005;48:5–26
  16. Dorschner W , Stolzenburg JU , Griebenow R , et al.   The elderly patient with urge incontinence or urge-stress incontinence (efficacy and cardiac safety of propiverine) . Aktuelle Urol . 2003;34:102–108
  17. Halaska M , Dorschner W , Frank M . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride . Neurourol Urodyn . 1994;13:428–430
  18. Szonyi G , Collas DM , Ding YY , et al.   Oxybutynin with bladder retraining for detrusor instability in elderly people (a randomised controlled trial) . Age Ageing . 1995;24:287–291
  19. Brambila EAS , Avila RGQ , Monterrubio JLL , et al.   Evaluation of the effectiveness and tolerance of oxybutynin in the treatment of unstable bladder in women . [translated from Spanish] Ginecol Obstet Mex . 2000;68:174–181
  20. Moisey CU , Stephenson TP , Brendler CB . The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride . Br J Urol . 1980;52:472–475
  21. Moore KH , Hay DM , Imrie AE , et al.   Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability . Br J Urol . 1990;66:479–485
  22. Tapp AJ , Cardozo LD , Versi E , et al.   The treatment of detrusor instability in post-menopausal women with oxybutynin chloride (a double blind placebo controlled study) . Br J Obstet Gynaecol . 1990;97:521–526
  23. Thuroff JW , Bunke B , Ebner A , et al.   Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity (oxybutynin versus propantheline versus placebo) . J Urol . 1991;145:813–816
  24. Dmochowski RR , Davila GW , Zinner NR , et al.  Transdermal Oxybutynin Study Group   Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence . J Urol . 2002;168:580–586
  25. Khullar V , Hill S , Laval K-U , et al.   Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release (a randomized, placebo-controlled trial) . Urology . 2004;64:269–275
  26. Millard R , Tuttle J , Moore K , et al.   Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity . J Urol . 1999;161:1551–1555
  27. Rentzhog L , Stanton SL , Cardozo L , et al.   Efficacy and safety of tolterodine in patients with detrusor instability (a dose-ranging study) . Br J Urol . 1998;81:42–48
  28. Rudy D , Cline K , Goldberg K , et al.   A multicenter randomised, placebo-controlled trial of trospium chloride in overactive bladder patients . 2004; Presented at the 34th Meeting of the International Continence Society; August 23-27, Paris, France. Abstract 144.
  29. Davila GW , Daugherty CA , Sanders SW  Transdermal Oxybutynin Study Group . A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence . J Urol . 2001;166:140–145
  30. Homma Y , Paick JS , Lee JG , et al.   Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder (a randomized, placebo-controlled trial) . BJU Int . 2003;92:741–747
  31. Leung HY , Yip SK , Cheon C , et al.   A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder . BJU Int . 2002;90:375–380
  32. Malone-Lee J , Shaffu B , Anand C , et al.   Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial . J Urol . 2001;165:1452–1456
  33. Abrams P , Freeman R , Anderstrom C , et al.   Tolterodine, a new antimuscarinic agent (as effective but better tolerated than oxybutynin in patients with an overactive bladder) . Br J Urol . 1998;81:801–810
  34. Dmochowski RR , Sand PK , Zinner NR , et al.  Transdermal Oxybutynin Study Group   Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence . Urology . 2003;62:237–242
  35. Madersbacher H , Halaska M , Voigt R , et al.   A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence . BJU Int . 1999;84:646–651
  36. Jünemann KP , Halaska M , Rittstein T , et al.   Propiverine vs. tolterodine (efficacy and tolerability in patients with detrusor overactivity) . 2003; Presented at the 33rd Annual Meeting of the International Continence Society; October 5-9, Florence, Italy.
  37. Chapple CR , Arano P , Bosch JL , et al.   Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study . BJU Int . 2004;93:71–77
  38. Van Kerrebroeck P , Kreder K , Jonas U , et al.   Tolterodine once-daily (superior efficacy and tolerability in the treatment of the overactive bladder) . Urology . 2001;57:414–421
  39. Pleil A , Reese P , Kelleher C , et al.   Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine . HEPAC . 2001;2:69–75
  40. Uebersax JS , Wyman JF , Shumaker SA , et al.   Short forms to assess life quality and symptom distress for urinary incontinence in women (the Incontinence Impact Questionnaire and the Urogenital Distress Inventory) . Neurourol Urodyn . 1995;14:131–139
  41. Kelleher CJ , Cardozo LD , Khullar V , et al.   A new questionnaire to assess the quality of life of urinary incontinent women . Br J Obstet Gynaecol . 1997;104:1374–1379
  42. Ware JE , Sherbourne CD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection . Med Care . 1992;30:473–483
  43. Gaudenz R . A questionnaire with a new urge-score and stress-score for the evaluation of female urinary incontinence . Geburtshilfe Frauenheilkd . 1979;39:784–792
  44. Shumaker SA , Wyman JF , Uebersax JS , et al.  Continence Program in Women (CPW) Research Group   Health-related quality of life measures for women with urinary incontinence (the Incontinence Impact Questionnaire and the Urogenital Distress Inventory) . Qual Life Res . 1994;3:291–306
  45. Amarenco G , Arnould B , Carita P , et al.   European psychometric validation of the CONTILIFE (a Quality of Life questionnaire for urinary incontinence) . Eur Urol . 2003;43:391–404
  46. Chapple C , Kelleher C , Perrault L . Darifenacin, an M3 selective receptor antagonist, improves quality of life in patients with overactive bladder . [abstract] Prog Urol . 2004;14(suppl 3):22
  47. Dorschner W , Stolzenburg JU , Griebenow R , et al.   Efficacy and cardiac safety of propiverine in elderly patients (a double-blind, placebo-controlled clinical study) . Eur Urol . 2000;37:702–708
  48. Kelleher CJ , Pleil AM , Reese PR , et al.   How much is enough and who says so? The case of the King’s Health Questionnaire and overactive bladder . Br J Obstet Gynaecol . 2004;111:605–612
  49. Diokno A , Sand P , Labasky R , et al.   Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder (a one-year study) . Int Urol Nephrol . 2002;34:43–49
  50. Kelleher CJ , Kreder KJ , Pleil AM , et al.   Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder . Am J Manag Care . 2002;8:S616–S630
  51. Lose G , Fantl JA , Victor A , et al.   Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction . Neurourol Urodyn . 1998;17:255–262
  52. Coyne K , Revicki D , Hunt T , et al.   Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire (the OAB-q) . Qual Life Res . 2002;11:563–574
  53. Coyne KS , Matza LS , Thompson CL . The responsiveness of the Overactive Bladder Questionnaire (OAB-q) . Qual Life Res . 2005;14:849–855
  54. Abrams P , Avery K , Gardener N , et al.   International Consultation on Incontinence (International Consultation on Incontinence Modular Questionnaire) . www.iciq.net J Urol . 2006;175:1063–1066
  55. Jaeschke R , Singer J , Guyatt GH . Measurement of health status (ascertaining the minimal clinically important difference) . Control Clin Trials . 1989;10:407–415
  56. Coyne K , Matza L , Kopp Z , et al.   Determining the minimally important difference of the Overactive Bladder Questionnaire (OAB-q) . J Urol . 2006;176:627–632

PII: S0090-4295(06)00771-0

doi: 10.1016/j.urology.2006.05.043

Urology
Volume 68, Issue 2, Supplement , Pages 38-48 , August 2006

Article Tools